Fusion IP, which commercialises university research, has signed an agreement with a pharmaceutical company utilising intellectual property out of the University of Sheffield, for the development of a known drug.
The agreement, which is worth over $500m per year is royalty-based, with limited milestone payments, will cover most of Fusion's net annual overheads.
The drug is already being marketed for a different treatment and as such the probability of a successful launch is considered to be high, the firm said.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The drug is currently at the second stage of development and is expected to make its first sales in 2015/16, with royalties to Fusion expected to peak at £1m per year.
Dr Andrew Tingey, Head of Licensing at Fusion, said: "This is an excellent licence for Fusion and demonstrates the value that can be unlocked through licensing the non spin-out opportunities within the Fusion pipeline."
The share price rose 10.39% to 42.5p by 12:40.
NR
-
Why you should not sell in MaySell in May is a strategy commonly applied to avoid poor returns - but does the theory still stand strong in 2024 or is it simply a fool's game, says Kalpana Fitzpatrick
-
Which region will see biggest house prices growth by 2028? What the latest Savills forecast saysNews House prices could see a turnaround over the next five years, according to Savills, as mortgage rates and cost of living pressures ease
